The Alzheimer’s drug, which could see full approval this summer, gets a ‘promising but inconclusive’ rating, due to its uncertain risk-benefit profile, the group says.
Novo Nordisk and Sanofi face pressure to cut insulin prices following Eli Lilly’s move
Marc Iskowitz comments on Eisai’s pricing transparency, Lecia Bushak discusses efforts to strengthen “gain-of-function” oversight, and Jack O’Brien addresses the recent controversy around a MrBeast video.
Inside pharma’s push to amend new drug-pricing law
Novartis CEO and incoming PhRMA board chair Vas Narasimhan says nullifying the Inflation Reduction Act’s nine-year timeline for small molecules tops his agenda.
‘Known unknowns’ make new pricing law a wild card for drug companies
The Inflation Reduction Act is the drug industry’s new talking point. Companies are raising awareness of the law’s unintended consequences, while reassuring investors that they can manage through the risk.
California Attorney General sues drugmakers over inflated insulin prices
The civil complaint alleges three pharmaceutical companies that control the insulin market are violating California law by unfairly and illegally driving up the cost of the drug
Ascending to Senate HELP committee chair, Bernie Sanders targets high drug prices, ‘cruel and dysfunctional’ healthcare system